期刊
JOURNAL OF CRANIO-MAXILLOFACIAL SURGERY
卷 46, 期 2, 页码 222-229出版社
CHURCHILL LIVINGSTONE
DOI: 10.1016/j.jcms.2017.11.004
关键词
Mesenchymal stem cells; Bone regeneration; Tissue engineering; Maxillofacial surgery; Cell therapy; Regenerative medicine
资金
- Red de Terapia Cellular of the Instituto de Salud Carlos III, Ministerio de Economia y Competitividad [RD16/0011/0003, RD16/0011/0022]
- Centro en Red de Medicina Regenerativa de Castilla y Leon
- Ministerio de Sanidad y Politica Social [EC10-255]
- Fondo de Investigaciones Sanitarias (FIS Intrasalud), Instituto de Salud Carlos III, Ministerio de Economia y Competitividad [PI10/01566]
- EU through European Regional Development Fund
- VI National R&D&I Plan, Iniciativa Ingenio, Consolider Program, CIBER Actions
- Instituto de Salud Carlos III
- European Regional Development Fund
Tissue engineering combining cross-linked serum scaffolds with bone-derived mesenchymal stem cells has displayed excellent results for repair of maxillofacial bone defects in animal models, but it had not been tested in humans yet. We present here a pilot clinical trial using autologous bone-derived mesenchymal stem cells (H-MSV) grown in a serum cross-linked scaffold (BioMax) for treatment of maxillary cysts in 9 patients. Cells obtained from alveolar bone were seeded in the BioMax scaffold prepared from autologous serum, expanded under GMP conditions, and subjected to osteogenic differentiation for 3-4 weeks before application. Evolution of the cystic cavity was followed by computerized tomography (CT) for 7 months. There was no inflammation or other adverse effects, and the CT density of the cyst interior increased significantly after the treatment. The ratio of the CT values after/before treatment was (mean +/- SE) 2.52 +/- 0.45; in contrast, the density of the contralateral control area of spongy alveolar bone without treatment did not change (ratio after/before, 0.99 +/- 0.14). In conclusion, cell therapy with BioMax could be considered as an alternative therapy for maxillary bone defects and other losses of bone substance. Further research with allogeneic cells would be useful for reducing costs and improving logistics. (c) 2017 European Association for Cranio-Maxillo-Facial Surgery. Published by Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据